Heat’s NSCLC combo clears Phase 1b
DURHAM, N.C.—In a Phase 1b trial evaluating its compound HS-110 and Opdivo (nivolumab) in non-small cell lung cancer, Heat Biologics Inc. announced that it had reached its efficacy endpoint and met the expansion criteria to advance into Phase 2. In addition, the Data Monitoring Committee determined that the Phase 1b safety endpoint was met and no additional toxicities seemed to arise compared to nivolumab alone.
Dr. Jeff Hutchins, Heat’s CSO and senior vice president of preclinical development, commented in part that “Although this is a small sample size and a non-randomized trial, we believe that this is an encouraging sign that the combination may be more effective than checkpoint therapy alone and could provide therapeutic benefit to a majority of lung cancer patients who do not respond well to checkpoint monotherapy. We remain focused on enrolling new patients to better characterize the objective response rate, durability of the response and associated immune activity.”